NPS Pharmaceuticals is an emerging development powerhouse that effectively brings biopharmaceuticals to patients with unmet medical needs. The company's lead clinical programs are innovative therapies for patients with rare gastrointestinal and endocrine disorders. NPS is advancing two late-stage programs. A New Drug Application is undergoing FDA review for GATTEX^® (teduglutide) as a treatment for adult short bowel syndrome (SBS) and a Phase 3 study has been completed for NATPARA™ (recombinant human parathyroid hormone (rhPTH 1-84)) in adult hypoparathyroidism. NPS is planning to submit its U.S. marketing application for NATPARA in 2012. The company's earlier stage pipeline includes two clinical stage calcilytic compounds, NPSP790 and NPSP795, with potential application in the rare disorder autosomal dominant hypocalcemia and hypercalciuria (ADHH).